Publications

. Rational development of gemcitabine-based nanoplatform for targeting SERPINB9/Granzyme B axis to overcome chemo-immune-resistance. Nat Commun. 2025-05-05;16(1):4176. doi: 10.1038/s41467-025-59490-y. PubMed PMID: 40325025; PMCID: PMC12053578.

. Rhodium(I)-Catalyzed Annulation of Bicyclo[1.1.0]butyl-Substituted Dihydroquinolines and Dihydropyridines. J Am Chem Soc. 2024-06-05; doi: 10.1021/jacs.4c04081. PubMed PMID: 38767459; PMCID: PMC11157536.

. Knocking down of Xkr8 enhances chemotherapy efficacy through modulating tumor immune microenvironment. J Control Release. 2024-06-01; doi: 10.1016/j.jconrel.2024.04.041. PubMed PMID: 38685385; PMCID: PMC11186464.

. Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations. Eur J Cancer. 2024-05-01;202114024. doi: 10.1016/j.ejca.2024.114024. PubMed PMID: 38513383; PMCID: PMC11053297.

. Impact of the 2021 CKD-EPI equation on anticancer pharmacotherapy in black and non-black cancer patients. Cancer Lett. 2024-04-01;216679. doi: 10.1016/j.canlet.2024.216679. PubMed PMID: 38307411; PMCID: PMC10939791.

. Knocking down of Xkr8 enhances chemotherapy efficacy through modulating tumor immune microenvironment. J Control Release. 2024-03-10; doi: 10.1016/j.jconrel.2024.03.011. PubMed PMID: 38471639.

. Synthetic lethal combination of CHK1 and WEE1 inhibition for treatment of castration-resistant prostate cancer. Oncogene. 2024-03-01; doi: 10.1038/s41388-024-02939-z. PubMed PMID: 38273024; PMCID: PMC11556418.

. Project Confirm: Accelerated Drug Approvals for CML-Letter. Clin Cancer Res. 2024-01-05;30(1):235-236. doi: 10.1158/1078-0432.CCR-23-2630. PubMed PMID: 38178775; PMCID: PMC10783536.

. Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy. Nat Commun. 2024-01-04;15(1):255. doi: 10.1038/s41467-023-44572-6. PubMed PMID: 38177179; PMCID: PMC10766965.

. Targeting Xkr8 via nanoparticle-mediated in situ co-delivery of siRNA and chemotherapy drugs for cancer immunochemotherapy. Nat Nanotechnol. 2023-02-01;18(2):193-204. doi: 10.1038/s41565-022-01266-2. PubMed PMID: 36424448; PMCID: PMC9974593.

. Improved antitumor activity against prostate cancer via synergistic targeting of Myc and GFAT-1. Theranostics. 2023-01-01;13(2):578-595. doi: 10.7150/thno.76614. PubMed PMID: 36632215; PMCID: PMC9830436.

. All Optimal Dosing Roads Lead to Therapeutic Drug Monitoring-Why Take the Slow Lane. JAMA Oncol. 2022-12-01;8(12):1733-1735. doi: 10.1001/jamaoncol.2022.4452. PubMed PMID: 36264552; PMCID: PMC9772116.

. Engineering a folic acid-decorated ultrasmall gemcitabine nanocarrier for breast cancer therapy: Dual targeting of tumor cells and tumor-associated macrophages. Acta Pharm Sin B. 2022-03-01;12(3):1148-1162. doi: 10.1016/j.apsb.2021.09.024. PubMed PMID: 35530140; PMCID: PMC9072252.

. Targeting metabotropic glutamate receptor 4 for cancer immunotherapy. Sci Adv. 2021-12-10;7(50):eabj4226. doi: 10.1126/sciadv.abj4226. PubMed PMID: 34890233; PMCID: PMC8664261.

. Author response to Cunha et al. J Immunother Cancer. 2021-07-01;9(7): doi: 10.1136/jitc-2021-003299. PubMed PMID: 34315823; PMCID: PMC8317086.

. DPP4(+) exosomes in AML patients' plasma suppress proliferation of hematopoietic progenitor cells. Leukemia. 2021-07-01;35(7):1925-1932. doi: 10.1038/s41375-020-01047-7. PubMed PMID: 33139859; PMCID: PMC10165724.

. Impact of upfront chemotherapy on overall survival in isolated myeloid sarcoma. Leukemia. 2021-04-01;35(4):1193-1196. doi: 10.1038/s41375-020-01017-z. PubMed PMID: 32814841.

. Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. J Immunother Cancer. 2021-04-01;9(4): doi: 10.1136/jitc-2020-001752. PubMed PMID: 33849924; PMCID: PMC8051405.

. A novel immunochemotherapy based on targeting of cyclooxygenase and induction of immunogenic cell death. Biomaterials. 2021-03-01;270120708. doi: 10.1016/j.biomaterials.2021.120708. PubMed PMID: 33578254; PMCID: PMC7910750.

. Tumor size-dependent abscopal effect of polydopamine-coated all-in-one nanoparticles for immunochemo-photothermal therapy of early- and late-stage metastatic cancer. Biomaterials. 2021-02-01;269120629. doi: 10.1016/j.biomaterials.2020.120629. PubMed PMID: 33387938; PMCID: PMC8466812.

. Blocking NHE1 stimulates glioma tumor immunity by restoring OXPHOS function of myeloid cells. Theranostics. 2021-01-01;11(3):1295-1309. doi: 10.7150/thno.50150. PubMed PMID: 33391535; PMCID: PMC7738877.

. The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. J Immunother Cancer. 2020-10-01;8(2): doi: 10.1136/jitc-2020-000810. PubMed PMID: 33077513; PMCID: PMC7574947.

. Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier. Theranostics. 2020-01-20;10(6):2463-2478. doi: 10.7150/thno.38973. PubMed PMID: 32194813; PMCID: PMC7052901.

. High Loading of Hydrophobic and Hydrophilic Agents via Small Immunostimulatory Carrier for Enhanced Tumor Penetration and Combinational Therapy. Theranostics. 2020-01-01;10(3):1136-1150. doi: 10.7150/thno.38287. PubMed PMID: 31938056; PMCID: PMC6956803.

. Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma. Nat Commun. 2019-07-18;10(1):3170. doi: 10.1038/s41467-019-11007-0. PubMed PMID: 31320621; PMCID: PMC6639324.

. Creatine based polymer for codelivery of bioengineered MicroRNA and chemodrugs against breast cancer lung metastasis. Biomaterials. 2019-07-01;21025-40. doi: 10.1016/j.biomaterials.2019.04.025. PubMed PMID: 31054369; PMCID: PMC6538300.

. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer. 2018-12-04;6(1):137. doi: 10.1186/s40425-018-0460-5. PubMed PMID: 30514386; PMCID: PMC6278156.

. Novel glucosylceramide synthase inhibitor based prodrug copolymer micelles for delivery of anticancer agents. J Control Release. 2018-10-28;288212-226. doi: 10.1016/j.jconrel.2018.09.011. PubMed PMID: 30223045; PMCID: PMC6177216.

. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J Immunother Cancer. 2018-05-14;6(1):35. doi: 10.1186/s40425-018-0342-x. PubMed PMID: 29754585; PMCID: PMC5950135.

. What's the FOX Got to Do with the KITten? Regulating the Lineage-Specific Transcriptional Landscape in GIST. Cancer Discov. 2018-02-01;8(2):146-149. doi: 10.1158/2159-8290.CD-17-1370. PubMed PMID: 29431674.

. Doxorubicin delivered by a redox-responsive dasatinib-containing polymeric prodrug carrier for combination therapy. J Control Release. 2017-07-28;25843-55. doi: 10.1016/j.jconrel.2017.05.006. PubMed PMID: 28501705; PMCID: PMC5525542.

. ER stress and impaired autophagy flux in neuronal degeneration and brain injury. Ageing Res Rev. 2017-03-01;343-14. doi: 10.1016/j.arr.2016.08.008. PubMed PMID: 27594375; PMCID: PMC5250579.

. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer. 2016-12-20;490. doi: 10.1186/s40425-016-0188-z. PubMed PMID: 28018601; PMCID: PMC5168808.

. An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. Nat Commun. 2016-11-07;713443. doi: 10.1038/ncomms13443. PubMed PMID: 27819653; PMCID: PMC5103075.

. Reply to: "miR-122 expression is not regulated during activation of hepatic stellate cells". J Hepatol. 2016-10-01;65(4):868. doi: 10.1016/j.jhep.2016.06.020. PubMed PMID: 27388922.

. Reply to V. Launay-Vacher, T. Shimokata et al, and C. Porta et al. J Clin Oncol. 2016-07-10;34(20):2430-1. doi: 10.1200/JCO.2016.67.2790. PubMed PMID: 27185845.

. Click chemistry: Straining to react. Nat Chem. 2016-04-01;8(4):296-7. doi: 10.1038/nchem.2485. PubMed PMID: 27001724.

. Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies. J Clin Oncol. 2016-01-10;34(2):110-6. doi: 10.1200/JCO.2014.59.7302. PubMed PMID: 26392101; PMCID: PMC4980565.

. Effective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapy. Biomaterials. 2015-10-01;67104-14. doi: 10.1016/j.biomaterials.2015.07.027. PubMed PMID: 26210177; PMCID: PMC4550547.

. Ovarian Cancer Survival and Chemotherapy Dosing, Body Mass Index, and Body Surface Area : Are We There Yet? JAMA Oncol. 2015-09-01;1(6):732-3. doi: 10.1001/jamaoncol.2015.1926. PubMed PMID: 26181495; PMCID: PMC4696392.

. The self-assembling camptothecin-tocopherol prodrug: An effective approach for formulating camptothecin. Biomaterials. 2015-09-01;62176-87. doi: 10.1016/j.biomaterials.2015.05.046. PubMed PMID: 26057133; PMCID: PMC4470812.

. Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia. Clin Cancer Res. 2015-05-01;21(9):2020-8. doi: 10.1158/1078-0432.CCR-14-0586. PubMed PMID: 25348512; PMCID: PMC4411210.

. Targeting ETV1 in gastrointestinal stromal tumors: tripping the circuit breaker in GIST? Cancer Discov. 2015-03-01;5(3):231-3. doi: 10.1158/2159-8290.CD-15-0116. PubMed PMID: 25749973.

. An improved D-α-tocopherol-based nanocarrier for targeted delivery of doxorubicin with reversal of multidrug resistance. J Control Release. 2014-12-28;196272-86. doi: 10.1016/j.jconrel.2014.10.016. PubMed PMID: 25456831; PMCID: PMC4267990.

. A PEG-Fmoc conjugate as a nanocarrier for paclitaxel. Biomaterials. 2014-08-01;35(25):7146-56. doi: 10.1016/j.biomaterials.2014.04.108. PubMed PMID: 24856103; PMCID: PMC4102141.